Jeffrey Ries
Upland, CANPI 1780647735
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $2,774 of the $3,191 with a category attached, or 86.9%. 4 manufacturers reported payments, led by Biohaven Pharmaceutical Holding Company Ltd. at 58.7% of the total.
Across 22 payments — averaging $145.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biohaven Pharmaceutical Holding Company Ltd.$2K
- Boehringer Ingelheim$1K
- Teva Pharmaceuticals USA, Inc.$63
- Travere Therapeutics, Inc.$1
Across 206 payments — averaging $4813.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$277K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$264K
- Axsome Therapeutics, Inc.$132K
- Supernus Pharmaceuticals, Inc.$105K
- AbbVie$91K
- Takeda Pharmaceuticals U.S.A., Inc.$41K
- plus $82K from 6 others
What the payments were for
- Travel & lodging$2,77487%
- Food & beverage$41713%
- Education$10%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd. | 11 | $1,873 |
| Boehringer Ingelheim | 9 | $1,254 |
| Teva Pharmaceuticals USA, Inc. | 1 | $63 |
| Travere Therapeutics, Inc. | 1 | $1 |
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.